Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: bello roufai d. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux É, Berton D, Bello-Roufai D, Guillemet C, Dupre PF, Faller É, Alexandre J, Hardy-Bressard AC, Collard O, Fabbro M, Provansal M, Kalbacher E, Genestie C, Pautier P. Blanc-Durand F, et al. Among authors: bello roufai d. Gynecol Oncol. 2020 Oct;159(1):129-135. doi: 10.1016/j.ygyno.2020.07.019. Epub 2020 Jul 25. Gynecol Oncol. 2020. PMID: 32723678
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
Romeo C, Le Saux O, Jacobs M, Joly F, Ferron G, Favier L, Fumet JD, Isambert N, Colombo PE, Sabatier R, Bastide L, Charreton A, Devouassoux-Shisheboran M, Gertych W, Dubot C, Bello Roufai D, Bataillon G, Berton D, Kalbacher E, Pautier P, Pomel C, Cornou C, Treilleux I, Lardy-Cleaud A, Ray-Coquard I. Romeo C, et al. Among authors: bello roufai d. Cancers (Basel). 2022 Jan 12;14(2):354. doi: 10.3390/cancers14020354. Cancers (Basel). 2022. PMID: 35053517 Free PMC article.
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Vaflard P, Paoletti X, Servois V, Tresca P, Pons-Tostivint E, Sablin MP, Ricci F, Loirat D, Hescot S, Torossian N, Bello Roufai D, Kamal M, Borcoman E, Le Tourneau C. Vaflard P, et al. Among authors: bello roufai d. Drugs R D. 2021 Dec;21(4):399-406. doi: 10.1007/s40268-021-00362-3. Epub 2021 Sep 25. Drugs R D. 2021. PMID: 34562258 Free PMC article.
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Oncogene. 2023 Jun;42(23):1951-1956. doi: 10.1038/s41388-022-02585-3. Epub 2023 Jan 7. Oncogene. 2023. PMID: 36611120
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Jeannot E, Latouche A, Bonneau C, Calméjane MA, Beaufort C, Ruigrok-Ritstier K, Bataillon G, Larbi Chérif L, Dupain C, Lecerf C, Popovic M, de la Rochefordière A, Lecuru F, Fourchotte V, Jordanova ES, von der Leyen H, Tran-Perennou C, Legrier ME, Dureau S, Raizonville L, Bello Roufai D, Le Tourneau C, Bièche I, Rouzier R, Berns EMJJ, Kamal M, Scholl S. Jeannot E, et al. Among authors: bello roufai d. Clin Cancer Res. 2021 Nov 1;27(21):5869-5877. doi: 10.1158/1078-0432.CCR-21-0625. Epub 2021 Jul 1. Clin Cancer Res. 2021. PMID: 34210686 Free PMC article.
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Oncogene. 2023 Apr;42(17):1417. doi: 10.1038/s41388-023-02615-8. Oncogene. 2023. PMID: 36922682 No abstract available.
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, Filotas P, Salomon A, Vodicska B, Servois V, Varkondi E, Gentien D, Tihanyi D, Tresca P, Lakatos D, Servant N, Deri J, du Rusquec P, Hegedus C, Bello Roufai D, Schwab R, Dupain C, Valyi-Nagy IT, Le Tourneau C. Petak I, et al. Among authors: bello roufai d. NPJ Precis Oncol. 2021 Jun 23;5(1):59. doi: 10.1038/s41698-021-00191-2. NPJ Precis Oncol. 2021. PMID: 34162980 Free PMC article.
18 results